23 July 2020
AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform is pleased to announce that the first healthy participants in the blinded Phase I clinical trial of AD-214 have been treated. One participant received AD-214 and one received placebo. Both participants have passed the 72-hour observation window without a dose limiting adverse event (DLAE).
CEO and Managing Director Dr Tim Oldham said, “We are pleased to have achieved this next important milestone in the initial clinical evaluation of AD-214. We also wish to express our gratitude to the volunteers who have agreed to participate in this trial and help advance a potential new therapy for patients battling interstitial lung disease, beginning with idiopathic pulmonary fibrosis.”